Mark Robert Zielinski, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sleep Deprivation | 12 | 2018 | 840 | 1.920 |
Why?
|
| Sleep Stages | 7 | 2014 | 691 | 1.430 |
Why?
|
| Nitric Oxide Synthase Type I | 3 | 2019 | 174 | 1.220 |
Why?
|
| Sleep | 13 | 2022 | 4750 | 1.210 |
Why?
|
| Substance P | 2 | 2017 | 333 | 0.980 |
Why?
|
| Physical Conditioning, Animal | 3 | 2013 | 366 | 0.820 |
Why?
|
| Delta Rhythm | 2 | 2019 | 81 | 0.750 |
Why?
|
| Receptors, Neurokinin-1 | 2 | 2017 | 132 | 0.600 |
Why?
|
| Cytokines | 7 | 2019 | 7344 | 0.590 |
Why?
|
| Somatostatin | 1 | 2019 | 447 | 0.580 |
Why?
|
| Polysomnography | 5 | 2017 | 1825 | 0.540 |
Why?
|
| Inflammasomes | 2 | 2022 | 532 | 0.530 |
Why?
|
| Circadian Rhythm | 4 | 2022 | 2570 | 0.500 |
Why?
|
| Cholera Toxin | 1 | 2017 | 559 | 0.490 |
Why?
|
| Adenosine Triphosphate | 2 | 2011 | 1993 | 0.460 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2014 | 4356 | 0.460 |
Why?
|
| Vagotomy | 1 | 2013 | 83 | 0.450 |
Why?
|
| Cerebral Cortex | 4 | 2019 | 5761 | 0.440 |
Why?
|
| Acute-Phase Reaction | 1 | 2013 | 91 | 0.440 |
Why?
|
| Brain-Derived Neurotrophic Factor | 2 | 2014 | 599 | 0.440 |
Why?
|
| Fatigue | 2 | 2019 | 1544 | 0.410 |
Why?
|
| Interleukin-1beta | 4 | 2014 | 999 | 0.410 |
Why?
|
| Olfactory Bulb | 1 | 2013 | 198 | 0.400 |
Why?
|
| Sleep, REM | 2 | 2012 | 593 | 0.390 |
Why?
|
| Telemetry | 1 | 2013 | 199 | 0.390 |
Why?
|
| Neuroimmunomodulation | 1 | 2013 | 177 | 0.380 |
Why?
|
| Adenomatous Polyps | 1 | 2012 | 108 | 0.370 |
Why?
|
| Receptors, Purinergic P2X7 | 2 | 2011 | 86 | 0.370 |
Why?
|
| 5'-Nucleotidase | 1 | 2012 | 161 | 0.370 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2013 | 250 | 0.370 |
Why?
|
| Neurotransmitter Agents | 1 | 2014 | 663 | 0.360 |
Why?
|
| Memory | 1 | 2019 | 2179 | 0.340 |
Why?
|
| Brain Chemistry | 1 | 2013 | 959 | 0.340 |
Why?
|
| Biphenyl Compounds | 1 | 2014 | 992 | 0.340 |
Why?
|
| Intestinal Neoplasms | 1 | 2012 | 311 | 0.330 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2013 | 1173 | 0.310 |
Why?
|
| Hypothalamus | 1 | 2013 | 998 | 0.300 |
Why?
|
| Autoimmune Diseases | 1 | 2019 | 2250 | 0.280 |
Why?
|
| Adenosine | 1 | 2012 | 834 | 0.280 |
Why?
|
| Somatosensory Cortex | 1 | 2010 | 511 | 0.270 |
Why?
|
| Mice, Inbred C57BL | 10 | 2021 | 22020 | 0.270 |
Why?
|
| Lipopolysaccharides | 2 | 2013 | 2209 | 0.270 |
Why?
|
| Movement | 1 | 2013 | 1474 | 0.260 |
Why?
|
| Memory Disorders | 1 | 2013 | 1197 | 0.260 |
Why?
|
| Inflammation | 5 | 2019 | 10755 | 0.250 |
Why?
|
| Glucose Tolerance Test | 1 | 2008 | 1174 | 0.250 |
Why?
|
| Neuroglia | 1 | 2011 | 944 | 0.250 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2008 | 277 | 0.240 |
Why?
|
| Mice, Knockout | 7 | 2021 | 14374 | 0.230 |
Why?
|
| Vagus Nerve | 2 | 2019 | 457 | 0.230 |
Why?
|
| Electroencephalography | 6 | 2021 | 6189 | 0.210 |
Why?
|
| Mice | 15 | 2021 | 81209 | 0.200 |
Why?
|
| Host-Pathogen Interactions | 1 | 2011 | 1447 | 0.200 |
Why?
|
| Brain | 6 | 2014 | 26951 | 0.200 |
Why?
|
| Peptide Fragments | 1 | 2014 | 5132 | 0.200 |
Why?
|
| Neurons | 3 | 2019 | 9424 | 0.190 |
Why?
|
| Animals | 21 | 2021 | 167960 | 0.190 |
Why?
|
| Vaccination | 1 | 2013 | 3359 | 0.190 |
Why?
|
| Electromyography | 3 | 2018 | 1388 | 0.170 |
Why?
|
| Immunity, Innate | 1 | 2011 | 3047 | 0.160 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2014 | 8158 | 0.160 |
Why?
|
| Anxiety | 1 | 2013 | 4538 | 0.150 |
Why?
|
| Infusions, Intraventricular | 1 | 2017 | 32 | 0.150 |
Why?
|
| Immunotoxins | 1 | 2017 | 175 | 0.140 |
Why?
|
| Cell Division | 1 | 2004 | 4463 | 0.130 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2021 | 893 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-fos | 2 | 2018 | 586 | 0.120 |
Why?
|
| Lymphoma | 1 | 2004 | 1899 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 1 | 2004 | 2640 | 0.110 |
Why?
|
| Male | 20 | 2021 | 359718 | 0.110 |
Why?
|
| Signal Transduction | 4 | 2017 | 23374 | 0.110 |
Why?
|
| Interleukin-1 Receptor Accessory Protein | 1 | 2011 | 5 | 0.100 |
Why?
|
| Wakefulness | 2 | 2017 | 1255 | 0.100 |
Why?
|
| Receptors, Interleukin-1 Type I | 1 | 2011 | 30 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2014 | 10826 | 0.100 |
Why?
|
| Genes, APC | 1 | 2012 | 145 | 0.100 |
Why?
|
| Reactive Oxygen Species | 1 | 2019 | 2138 | 0.100 |
Why?
|
| Maze Learning | 1 | 2013 | 477 | 0.090 |
Why?
|
| Purinergic P2 Receptor Agonists | 1 | 2010 | 13 | 0.090 |
Why?
|
| Purinergic P2 Receptor Antagonists | 1 | 2010 | 72 | 0.090 |
Why?
|
| Receptors, Pattern Recognition | 1 | 2011 | 83 | 0.090 |
Why?
|
| Electrodes, Implanted | 1 | 2014 | 833 | 0.090 |
Why?
|
| Mice, Transgenic | 2 | 2019 | 9530 | 0.090 |
Why?
|
| Space Perception | 1 | 2013 | 464 | 0.090 |
Why?
|
| Bed Rest | 1 | 2009 | 83 | 0.080 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2013 | 448 | 0.080 |
Why?
|
| RNA, Messenger | 3 | 2014 | 12762 | 0.080 |
Why?
|
| Rats | 4 | 2013 | 23709 | 0.080 |
Why?
|
| Adenosine Triphosphatases | 1 | 2012 | 833 | 0.070 |
Why?
|
| Functional Laterality | 1 | 2014 | 2253 | 0.070 |
Why?
|
| Phototherapy | 1 | 2011 | 368 | 0.070 |
Why?
|
| Random Allocation | 1 | 2012 | 2394 | 0.070 |
Why?
|
| Mental Recall | 1 | 2013 | 1206 | 0.070 |
Why?
|
| Interleukin-1 | 1 | 2010 | 1249 | 0.070 |
Why?
|
| Brain Waves | 1 | 2010 | 401 | 0.070 |
Why?
|
| Curcumin | 1 | 2007 | 99 | 0.070 |
Why?
|
| Influenza Vaccines | 1 | 2013 | 766 | 0.070 |
Why?
|
| Glucose Intolerance | 1 | 2010 | 580 | 0.060 |
Why?
|
| Swimming | 1 | 2006 | 207 | 0.060 |
Why?
|
| Cumulative Trauma Disorders | 1 | 2007 | 148 | 0.060 |
Why?
|
| RNA, Viral | 1 | 2013 | 2838 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2013 | 6238 | 0.060 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 1 | 2004 | 58 | 0.060 |
Why?
|
| Myositis | 1 | 2007 | 269 | 0.060 |
Why?
|
| Stress, Psychological | 1 | 2019 | 4446 | 0.060 |
Why?
|
| Body Temperature | 1 | 2006 | 777 | 0.050 |
Why?
|
| Time Factors | 3 | 2013 | 40139 | 0.050 |
Why?
|
| Muscular Diseases | 1 | 2007 | 551 | 0.050 |
Why?
|
| Schizophrenia | 1 | 2021 | 6915 | 0.050 |
Why?
|
| Sensory Gating | 1 | 2021 | 47 | 0.050 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 6538 | 0.050 |
Why?
|
| Gene Expression | 1 | 2013 | 7587 | 0.040 |
Why?
|
| Racemases and Epimerases | 1 | 2021 | 112 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2004 | 2014 | 0.040 |
Why?
|
| Necrosis | 1 | 2004 | 1612 | 0.040 |
Why?
|
| Anxiety Disorders | 1 | 2011 | 2714 | 0.040 |
Why?
|
| Rest | 1 | 2004 | 914 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 18137 | 0.040 |
Why?
|
| Humans | 12 | 2022 | 760613 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2007 | 2985 | 0.030 |
Why?
|
| Exercise Test | 1 | 2004 | 2128 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2004 | 6216 | 0.030 |
Why?
|
| Social Behavior | 1 | 2021 | 1131 | 0.030 |
Why?
|
| Mass Screening | 1 | 2008 | 5422 | 0.030 |
Why?
|
| Evoked Potentials | 1 | 2018 | 1036 | 0.020 |
Why?
|
| Female | 8 | 2021 | 391246 | 0.020 |
Why?
|
| Receptors, Purinergic P2Y1 | 1 | 2011 | 42 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2008 | 12914 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 15840 | 0.020 |
Why?
|
| Psychometrics | 2 | 2011 | 3051 | 0.020 |
Why?
|
| Personality Inventory | 1 | 2011 | 1018 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2004 | 16932 | 0.020 |
Why?
|
| Actigraphy | 1 | 2009 | 518 | 0.020 |
Why?
|
| Aged | 4 | 2011 | 169143 | 0.010 |
Why?
|
| Psychomotor Performance | 1 | 2009 | 1878 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2011 | 2896 | 0.010 |
Why?
|
| Energy Intake | 1 | 2006 | 2129 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2007 | 4035 | 0.010 |
Why?
|
| Affect | 1 | 2006 | 1480 | 0.010 |
Why?
|
| Depressive Disorder | 1 | 2011 | 3726 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2011 | 8556 | 0.010 |
Why?
|
| Middle Aged | 2 | 2009 | 220359 | 0.010 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2007 | 1796 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2006 | 2696 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2009 | 7022 | 0.010 |
Why?
|
| Comorbidity | 1 | 2011 | 10553 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2010 | 6379 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2009 | 64981 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2011 | 26179 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2009 | 39262 | 0.000 |
Why?
|
| Quality of Life | 1 | 2009 | 13308 | 0.000 |
Why?
|
| Young Adult | 1 | 2011 | 58748 | 0.000 |
Why?
|
| Child | 1 | 2011 | 79799 | 0.000 |
Why?
|
| Adult | 1 | 2006 | 220007 | 0.000 |
Why?
|